Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Transform Your Shoes into Electric Roller Skates at Home! Discover how to create your own electric roller skate shoes with our step-by-step tutorial! Equip yourself with 20 DC motors with wheels, ...

On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

DIY Tattoo Machine Made from a Pen – Easy Tutorial You Won’t Believe! Nicole Kidman Files for Divorce from Keith Urban After 19 Years of Marriage Gen Z is reviving this boring job that millennials and ...

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year. Still, even as ...

Automotive BMS must undergo rigorous testing to verify that it meets stringent performance and safety standards. BMS emulation involves using hardware and software tools to simulate the behavior of a ...

Details on a BMS based on electrochemical impedance spectroscopy (EIS). BMS advances to keep pace with EV rising complexity. Building better battery models based on EIS characterization. The ...

Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...

Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halting (PDF) further development months after filing to run a phase 3 trial. The Big Pharma disclosed ...